Related Experiment Video
Updated: Aug 13, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Liver steatosis in HIV-infected patients
1Service des Maladies Infectieuses et Tropicales CHU, 10 Boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon, France. lionel.piroth@chu-dijon.fr
Abstract:
Liver steatosis, defined as abnormal fat accumulation in hepatocytes, may be related to different pathogenic mechanisms, in particular metabolic abnormalities, toxic injuries, and viral infections. Since most of these mechanisms are frequently encountered in HIV-infected patients, and since HIV infection per se and antiretroviral treatments may be involved in the pathogenesis of liver steatosis, it could be speculated that HIV-infected patients are at a high risk of developing the condition. However, studies on steatosis in HIV-infected patients are still rare and do not reveal any significant increase, prevalence or clinical impact. Nevertheless, while waiting for prospective studies in HIV-infected patients, improved recognition, diagnosis and management of steatosis are required in these patients.
Related Concept Videos
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatitis
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

